文献速递医学教育与科研方法

改善临床试验报告和方案中的结局报告:临床试验计划终点报告工具(InsPECT)研究方案

Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT).
PubMed 文献 · Trials · 2019-03-06

针对临床试验结局报告不充分、质量差的问题,本研究拟依据EQUATOR网络的方法学框架开发InsPECT工具,作为SPIRIT和CONSORT报告规范的扩展。开发包括创建候选条目清单、三轮国际德尔菲研究和面对面专家共识会议,最终形成试验方案和报告中结局报告必备条目的标准。

要点

  • InsPECT将作为SPIRIT和CONSORT的扩展,提供结局报告的标准。
  • 开发采用EQUATOR网络方法学框架,含德尔菲研究和共识会议。
  • 目标是通过标准化结局报告减少研究浪费并改善患者结局。

核心结论

  • InsPECT将提供基于证据和共识的标准,聚焦于临床试验的结局报告,可应用于不同疾病领域、研究人群和结局。
  • InsPECT将支持试验结局报告的标准化,最大化试验可用性、减少偏倚、促进试验重复、改善试验设计和执行,最终减少研究浪费并帮助改善患者结局。

研究设计与样本

  • InsPECT SPIRIT和CONSORT扩展将依据EQUATOR网络创建的报告指南开发方法学框架进行开发。
  • 开发包括三步:创建候选结局报告条目初始清单;进行三轮国际德尔菲研究;举行面对面专家共识会议。

主要发现

  • 临床试验中不充分和劣质的结局报告是已有充分记录的问题,妨碍研究者评估、重复、综合和建立在研究发现之上,并影响患者、临床医生和决策者的循证决策。
  • 候选条目清单将从专家咨询和对试验方案与报告中结局报告现有指南的范围综述中合成。
  • 德尔菲研究将识别额外候选条目,并由利益相关者用9点李克特量表评估候选条目的重要性。
  • 共识会议讨论将由独立促进者引导,并参考原始文献中的实证证据和德尔菲研究收集的意见(汇总排名和评论)。
  • 将全程采用整合知识转化方法以促进实施和传播,此外还有标准的开发后活动。

关键数值与推荐

  • 德尔菲研究采用9点李克特量表评估候选条目的重要性。
  • 利益相关者包括试验报告和方案作者、系统综述作者、生物统计学家和流行病学家、报告指南开发者、临床医生、期刊编辑和研究伦理委员会代表。
  • 共识会议旨在最终确定试验方案和报告中各自必备的结局报告条目集。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inadequate and poor quality outcome reporting in clinical trials is a well-documented problem that impedes the ability of researchers to evaluate, replicate, synthesize, and build upon study findings and impacts evidence-based decision-making by patients, clinicians, and policy-makers. To facilitate harmonized and transparent reporting of outcomes in trial protocols and published reports, the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT) is being developed. The final product will provide unique InsPECT extensions to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) and CONSORT (Consolidated Standards of Reporting Trials) reporting guidelines. METHODS: The InsPECT SPIRIT and CONSORT extensions will be developed in accordance with the methodological framework created by the EQUATOR (Enhancing the Quality and Transparency of Health Research Quality) Network for reporting guideline development. Development will consist of (1) the creation of an initial list of candidate outcome reporting items synthesized from expert consultations and a scoping review of existing guidance for reporting outcomes in trial protocols and reports; (2) a three-round international Delphi study to identify additional candidate items and assess candidate item importance on a 9-point Likert scale, completed by stakeholders such as trial report and protocol authors, systematic review authors, biostatisticians and epidemiologists, reporting guideline developers, clinicians, journal editors, and research ethics board representatives; and (3) an in-person expert consensus meeting to finalize the set of essential outcome reporting items for trial protocols and reports, respectively. The consensus meeting discussions will be independently facilitated and informed by the empirical evidence identified in the primary literature and through the opinions (aggregate rankings and comments) collected via the Delphi study. An integrated knowledge translation approach will be used throughout InsPECT development to facilitate implementation and dissemination, in addition to standard post-development activities. DISCUSSION: InsPECT will provide evidence-informed and consensus-based standards focused on outcome reporting in clinical trials that can be applied across diverse disease areas, study populations, and outcomes. InsPECT will support the standardization of trial outcome reporting, which will maximize trial usability, reduce bias, foster trial replication, improve trial design and execution, and ultimately reduce research waste and help improve patient outcomes.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Butcher NJ, Monsour A, Mew EJ, et al. Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT). Trials. 2019. PMID: 30841935. doi:10.1186/s13063-019-3248-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。